NImmune Biopharma

Pioneering Precision Immunology🧬 | Late-Stage Biopharma💊 | Biomarker-Driven Therapies🔬 | Computational Modeling & Bioinformatics📊 | Tackling UC & Crohn's

[NImmune Biopharma @NImmuneBio]

On #WorldIBDDay, we reflect on the need for improved therapies that go beyond symptom control to address underlying root causes of IBD, and we are excited by the clinical validation of omilancor and NIM-1324, two oral LANCL2 medicines for ulcerative colitis and Crohn’s disease.

[NImmune Biopharma @NImmuneBio]

NImmune presented two abstracts at #DDW2026 with new insights into NIM-1324 safety, tolerability and evidence of LANCL2 target engagement, highlighting strong performance vs. current IBD therapies. Read more: https://t.co/vBLqK6louU

#DrugDevelopment #PrecisionMedicine #IBD

[The NIMML Institute @NIMMLab]

At #IMMUNOLOGY2026, we presented new data showing that LANCL2 medicines reduced respiratory disease, lung lesions and inflammation and increased lung Tregs in mouse models of asthma. Read our recent article to learn more: https://t.co/EMuXW1GFuV

[The NIMML Institute @NIMMLab]

Proud to share that @NImmuneBio will present new data on LANCL2 medicines at #IMMUNOLOGY2026, highlighting novel immunometabolic approaches with pipeline‑in‑a‑drug potential across inflammatory, autoimmune and neurodegenerative diseases. Read more: https://t.co/pcwB5l8OW5

[NImmune Biopharma @NImmuneBio]

Dr. Josep Bassaganya‑Riera is launching a clinical program advancing NIM‑1324 a next‑gen oral, once-daily LANCL2 therapeutic for IBD. NIM‑1324 targets both gut and extraintestinal disease through a systemic approach. Results will be presented at #DDW2026.

https://t.co/Q6k8diIDPS

[NImmune Biopharma @NImmuneBio]

New research in @Nature Magazine Scientific Reports shows omilancor improves cognition and reduces Alzheimer’s symptoms. This reinforces the therapeutic potential of omilancor, our lead product candidate for inflammatory and autoimmune disease.

Read more: https://t.co/26pjs1ZIOj

[NImmune Biopharma @NImmuneBio]

Dr. Josep Bassaganya-Riera, our Founder & CEO, was featured on the Biotech Blueprint podcast, delving into the scientific underpinnings of how NImmune’s lead candidates outperform current IBD drugs in efficacy and safety. Listen here: https://t.co/u255lAXi4S

[NImmune Biopharma @NImmuneBio]

Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on @BiotechnologyPa’s Biotech Insiders podcast as he shares how AI is transforming drug development and why high-precision immunology is key to disrupting the I&I disease treatment paradigm. https://t.co/0P8cH8SzpO

[The NIMML Institute @NIMMLab]

We are excited to contribute to the 3rd edition of “Goals in Nutrition Science” (2025–2030), a forthcoming initiative from @FrontNutrition sharing global perspectives on the future of the field, incl. a section on immunometabolism from our founder Josep Bassaganya-Riera. (1/2)

[NImmune Biopharma @NImmuneBio]

ICYMI: Eli Lilly and Nvidia recently announced a new partnership to leverage AI capabilities for drug discovery & development.

At NImmune, we've successfully demonstrated how advanced AI models can greatly accelerate therapeutic discovery & development. https://t.co/DHHsAel6FZ

[NImmune Biopharma @NImmuneBio]

Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on the Honestquo VC Podcast as he discusses pioneering tech in precision medicine and shares insights from his journey as a biotech founder.
Listen here: https://t.co/6xk7NrwPzc

#Biopharma #AI #PrecisionMedicine

[NImmune Biopharma @NImmuneBio]

Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: https://t.co/orjHldf0K6

[NImmune Biopharma @NImmuneBio]

Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.

[NImmune Biopharma @NImmuneBio]

Excited to share that our Founder & CEO, Dr. Josep Bassaganya-Riera is featured in a Q&A by CityBiz, discussing NImmune’s mission to advance our first-and best-in-class, biomarker-driven immunoregulatory therapeutics. Read it here: https://t.co/Lo3roR6H3w

[NImmune Biopharma @NImmuneBio]

New #DDW2025 data: once-daily oral omilancor outperformed anti-TL1A in IBD on efficacy & safety. Results show reversal of Treg depletion & mitochondrial dysfunction in UC. Best-in-class profile supports NDA path by 2027. Read more: https://t.co/gVLv60HhoR

[NImmune Biopharma @NImmuneBio]

Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: https://t.co/uYI1JVPSvV

[NImmune Biopharma @NImmuneBio]

Thrilled to see @NIMMLab’s new #TITANX applications in @AnnualReviews. This #AI platform is driving our drug pipeline, from omilancor to NIM-1324, accelerating #PrecisionMedicine for #immunology. Keep innovating!

[The NIMML Institute @NIMMLab]

Excited to share new case studies in @AnnualReviews showing how our TITAN-X #AI platform fuels next-gen #immunology & #inflammation therapies. By unlocking novel targets like LANCL2, we’re advancing #PrecisionMedicine. Read the peer-reviewed article here: https://t.co/eQ9DXsRwOl

[NImmune Biopharma @NImmuneBio]

Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: https://t.co/uEugnyXVBv

[NImmune Biopharma @NImmuneBio]

Our Founder and CEO, Dr. Bassaganya-Riera, recently edited a collection of articles for @FrontiersIn Immunology on new computational modeling methods to study alloimmune T-cell responses. Read the full editorial here: https://t.co/ZVrHBSIhp0 #BioPharma

[NImmune Biopharma @NImmuneBio]

We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety profile, novel mechanism and combination therapies of omilancor & TL1A. Read more: https://t.co/E2023TCRpR